Bio-Path announces third pre-clinical milestone for BP1001-A in obesity/Type 2 diabetes

BIO-PATH HOLDINGS, INC.

BP1001-A rescues AKT activity decrease in liver cells, preventing insulin resistance.
Data confirm potential of BP1001-A to treat obesity in Type 2 diabetes patients.
Pre-clinical testing in HepG2 liver cell model supports earlier results in muscle cells.
Next step: mouse model study; IND filing expected in 2025 for Phase 1 trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.